Company
Headquarters: London, United Kingdom
Employees: 9
CEO: Mr. Clive Richardson
$37.6 Million
USD as of July 1, 2025
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $309.91 B |
Vertex Pharmaceuticals Incorporated | $117.36 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $59.14 B |
Marinomed Biotech AG | $58.56 B |
Company | Market Cap (USD) |
---|---|
Lilly | $699.59 B |
Johnson & Johnson | $374.29 B |
AbbVie | $336.94 B |
Novo Nordisk | $309.91 B |
UnitedHealth Group | $279.90 B |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Akari Therapeutics, Plc has the following listings and related stock indices.
Stock: NASDAQ: AKTX wb_incandescent